Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
Conditions
Brief summary
This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.
Detailed description
PRIMARY OBJECTIVES: I. To identify SNPs associated with delayed MTX clearance. II. To explore any association between SNPs and increased toxicity. OUTLINE: This is an observational study. Participants undergo blood sample collection and have their medical records reviewed on study.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Sponsors
Ohio State University Comprehensive Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \* Adult (age ≥ 18 years at diagnosis) * Diagnosis of DLBCL or PCNSL * Planned to undergo treatment with HDMTX (≥ 3 g/m\^2) at the James Cancer Hospital. Note: patients with CKD are eligible to participate regardless of eGFR provided the treating physician is planning a dose of HDMTX of at least 3 g/ m\^2. * Ability to provide informed consent.
Exclusion criteria
* \* Patients with a currently active second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation * Pregnancy (positive serum or urine pregnancy test), lactating or breast feeding * Prisoners or incarcerated patients * Total bilirubin \> 5 mg/dL
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SNPs (single nucleotide polymorphisms) associated with delayed MTX clearance | Up to 24 weeks | Determine the SNPs associated with delayed methotrexate clearance |
Countries
United States
Outcome results
None listed